Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Eric S. Mullins, MD, Christine M. Knoll, MD, Amy L. Dunn, MD, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 1409.

https://doi.org/10.1182/blood.V128.22.1409.1409

Published: 2016

Journal Articles

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Amy L. Dunn, MD, Alexis A. Thompson, MD MPH, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3778.

https://doi.org/10.1182/blood.V128.22.3778.3778

Published: 2016

Journal Articles

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 2592.

https://doi.org/10.1182/blood.V128.22.2592.2592

Published: 2016

Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD

Blood (2016) 128 (22): 2594.

https://doi.org/10.1182/blood.V128.22.2594.2594

Published: 2016

Journal Articles

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Dyck-Jones Jacqueline, PhD, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3801.

https://doi.org/10.1182/blood.V128.22.3801.3801

Published: 2016

Journal Articles

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Vasily Mamonov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 2585.

https://doi.org/10.1182/blood.V128.22.2585.2585

Published: 2016

Journal Articles

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

Alice D. Ma, MD, Robert Klamroth, Marilyn J. Manco-Johnson, MD, Werner Engl, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 1105.

https://doi.org/10.1182/blood.V126.23.1105.1105

Published: 2015

Journal Articles

Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures

Brigitte Brand, Ralph A. Gruppo, MD, Tung T. Wynn, Laimonas Griskevicius, Maria Fernanda Lopez Fernandez, Thomas Dvorak, Lisa Patrone, Brigitt E. Abbuehl

Blood (2015) 126 (23): 2299.

https://doi.org/10.1182/blood.V126.23.2299.2299

Published: 2015

Journal Articles

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

Marilyn J. Manco-Johnson, MD, Alice D. Ma, MD, Robert Klamroth, Werner Engl, Lorena Griparic, PhD, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 2300.

https://doi.org/10.1182/blood.V126.23.2300.2300

Published: 2015

Journal Articles

An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a

Pratima Chowdary, Barbara Konkle, MD, Tadashi Matsushita, MD PhD, Werner Engl, Lisa Patrone, Brigitt E. Abbuehl

Blood (2015) 126 (23): 3522.

https://doi.org/10.1182/blood.V126.23.3522.3522

Published: 2015

Journal Articles

Pharmacokinetics, Efficacy and Safety Of a Recombinant Factor IX (BAX326) In Previously-Treated Pediatric Patients < 12 Years Of Age With Severe Or Moderately Severe Hemophilia B

Tomasz Urasinski, Oleksandra Stasyshyn, Tatiana Andreeva, Luminita Rusen, Farida Perina, MyungShin Oh, Miranda Chapman, Borislava G Pavlova, Wing Yen Wong, Brigitt E. Abbuehl

Blood (2013) 122 (21): 1118.

https://doi.org/10.1182/blood.V122.21.1118.1118

Published: 2013

Journal Articles

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

Jerzy Windyga, MD, PhD, Toshko Lissitchkov, MD, PhD, Oleksandra Stasyshyn, MD, Vasily Mamonov, MD, Luminita Rusen, MD, PhD, José Luis Lamas, MD, Myungshin Oh, PhD, Miranda Chapman, Sandor Fritsch, PhD, Borislava G Pavlova, PhD, Wing Yen Wong, MD, Brigitt E. Abbuehl, MD

Blood (2012) 120 (21): 2222.

https://doi.org/10.1182/blood.V120.21.2222.2222

Published: 2012

Journal Articles

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Gerald Spotts, PhD, Brigitt E. Abbuehl, MD, Huong D. Luu, PharmD, Clara K. Song, PharmD, Jacqueline A. Dyck-Jones, Norma Guzman-Becerra, LieLing Wu, MyungShin Oh, Michael Zoerer, Judith Jill V. Sosa, Darby E. Stephens, Linda J. Yamamoto, MD, Bruce M. Ewenstein, MD, PhD

Blood (2010) 116 (21): 3670.

https://doi.org/10.1182/blood.V116.21.3670.3670

Published: 2010

NARROW

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a

Pharmacokinetics, Efficacy and Safety Of a Recombinant Factor IX (BAX326) In Previously-Treated Pediatric Patients < 12 Years Of Age With Severe Or Moderately Severe Hemophilia B

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only